Alaunos Therapeutics Inc (TCRT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.86M
Last updated: Nov 17, 2026 at 4:15 PM ET
Alaunos Therapeutics Inc (TCRT) Statistics
Alaunos Therapeutics (TCRT) has a market cap of $6.86M and an enterprise value of $6.24M. It kept -120766.67% of revenue as net income over the last 12 months. Its share count is up 19.31% from a year earlier.
Total Valuation
Enterprise value is 8.97% below the market cap, as cash exceeds debt.
| Market Cap | $6.86M |
|---|---|
| Enterprise Value | $6.24M |
| Latest price (Nov 17, 2026) | $1.66 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 44.11% over 52 weeks and trades 1.22% above its 50-day average.
| Beta (1Y) | 0.94 |
|---|---|
| 52-Week Change | -44.11% |
| 1-Month Change | -46.96% |
| 3-Month Change | -11.70% |
| 6-Month Change | -33.60% |
| 5-Year Change | -99.13% |
| 10-Year Change | -99.77% |
| Total Return (1Y) | -44.11% |
| Total Return (3Y CAGR) | -45.23% |
| Total Return (5Y CAGR) | -62.10% |
| Return vs SPY (1Y) | -61.86% |
| Max Drawdown (1Y) | -82.97% |
| Max Drawdown (3Y) | -97.33% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $1.64 |
| 200-Day Average | $2.26 |
| 52-Week Range | $0.72 to $4.50 |
| RSI (14 Days) | 46.1 |
| Average Volume (20 Days) | 497.68K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.14x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.14x |
|---|---|
| Quick Ratio | 1.14x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -373.12% and return on assets is -188.89% over the last 12 months.
| Return on Equity (ROE) | -373.12% |
|---|---|
| Return on Assets (ROA) | -188.89% |
| Return on Capital Employed (ROCE) | -369.93% |
| Asset Turnover | 0.00x |
Scores
TCRT has an Altman Z-Score of -680.26, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -680.26 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $3.00K over the last 12 months is down 57.14% from the 12 months before.
| Revenue | $3.00K |
|---|---|
| Revenue Growth (YoY) | -57.14% |
| Gross Profit | $3.00K |
| Operating Income | -$3.63M |
| Pretax Income | -$3.59M |
| Net Income | -$3.62M |
| EBITDA | -$3.56M |
| EBIT | -$3.59M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 50.57% of the $1.92M in total assets.
| Cash and Equivalents | $615.00K |
|---|---|
| Total Debt | $0 |
| Net Cash | $615.00K |
| Net Cash Per Share | $0.24 |
| Working Capital | $129.00K |
| Shareholder Equity | $971.00K |
| Book Value Per Share | $0.37 |
| Total Assets | $1.92M |
| Total Liabilities | $947.00K |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$2.31M |
|---|---|
| FCF Per Share | -$0.55 |
| Depreciation and Amortization | $32.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -121033.33%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -121033.33% |
| Pretax Margin | -119733.33% |
| Net Margin | -120766.67% |
| EBITDA Margin | -118666.67% |
| EBIT Margin | -119733.33% |
Growth
Revenue fell 88.04% a year over 3 years.
| Revenue Growth (3Y CAGR) | -88.04% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -47.03% |
| Tangible Book Per Share Growth (2Y CAGR) | -47.03% |
Dividends and Yields
TCRT does not pay a dividend.
| Buyback Yield | -21.19% |
|---|---|
| Shareholder Yield | -21.19% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 18, 2024.
| Last Split Date | Jul 18, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TCRT
What is TCRT's market cap?
Alaunos Therapeutics has a market cap of $6.86M. Its enterprise value, which adds debt and subtracts cash, is $6.24M.
How many shares of TCRT are outstanding?
Alaunos Therapeutics has 2.60M shares outstanding. The count is up 19.31% from a year earlier.
Does TCRT pay a dividend?
No. Alaunos Therapeutics does not pay a dividend.
How much debt does TCRT have?
Alaunos Therapeutics has $0 of total debt and $615.00K of cash and equivalents, a net cash position of $615.00K.
TCRT pages: Overview, Charting, Earnings, Financials, Statistics, Competitors